Phage Therapy Group
The Phage Therapy Group focuses on developing bacteriophage-based therapies to combat antibiotic-resistant bacterial infections. We specialize in personalized phage therapy, investigating phage pharmacokinetics/pharmacodynamics, and understanding host-pathogen interactions. Our translational research includes clinical trials, compassionate use cases, and economic modeling to reduce antimicrobial resistance. We also explore the role of bacteriophages in sepsis management and novel immune responses facilitated by phages.
Key research topics include
- Personalized Bacteriophage Therapy: Developing tailored phage treatments for antibiotic-resistant bacterial infections.
- Phage Pharmacokinetics and Pharmacodynamics: Investigating how bacteriophages interact with the human body to optimize clinical outcomes.
- Sepsis Management: Studying the role of phages in managing sepsis and critical care infections.
- Host-Pathogen Interactions: Exploring how bacteriophages affect host immune responses and pathogen behavior.
- Economic Modeling of Antimicrobial Resistance: Quantifying the clinical and economic impact of reducing resistance in healthcare settings.
- Phage Immune Neutralization: Understanding and mitigating immune system responses that neutralize phage therapy.
Recent publications
Immune responses to phage therapy in humans: A review.
Differences in Phage Recognition and Immunogenicity Contribute to Divergent Human Immune Responses to Escherichia coli and Klebsiella pneumoniae Phages.
Personalized bacteriophage therapy for difficult-to-treat infections.
Using a human colonoid-derived monolayer to study bacteriophage translocation.
Translating phage therapy into the clinic: Recent accomplishments but continuing challenges.
Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): protocol for an open-label, single-arm trial.
L-Form Switching in Escherichia coli as a Common β-Lactam Resistance Mechanism.
Biological foundations of successful bacteriophage therapy.
Co-Occurrence of Multidrug Resistant Klebsiella pneumoniae Pathogenic Clones of Human Relevance in an Equine Pneumonia Case.
Fine capsule variation affects bacteriophage susceptibility in Klebsiella pneumoniae ST258
Safety of bacteriophage therapy in severe Staphylococcus aureus infection.
Polyclonal Staphylococcus aureus Bacteremia.
Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection.
| Name | Position |
| Kiran Bosco | Student |
| Laela Bouaou | Research Assistant |
| Clare Fisher | Research Assistant |
| Emily Mascord | Executive Assistant to Professor Jon Iredell |
| Dr Holly Sinclair | Infectious Diseases Physician, Westmead Hospital |
| Dr Jackie Chan | Genomics Coordinator |
SUPPORT US
With your support, we can continue to explore groundbreaking research and improved health outcomes for people everywhere.
Share
